Phase 4
N=92
Ideal Steroids for Asthma Treatment in the PICU
Asthma Childhood
Bottom Line
View on ClinicalTrials.gov: NCT03900624 ↗Enrolled (actual)
92
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcome: Primary: Length of Stay — 2.9; 2.9 days — p=0.632
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Dexamethasone (Drug)
- Age
- Pediatric · 5+ yrs
- Sex
- All
- Sponsor
- Johns Hopkins All Children's Hospital
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Length of Stay |
2.9; 2.9 | 0.632 |
| SECONDARY Duration of Continuous Nebulized Albuterol |
1; 0.8 | 0.725 |
Summary
Determine if differences in (1) pediatric intensive care unit length of stay, (2) continuous nebulized albuterol duration, and (3) a composite outcome of advanced asthma therapy incidence including use of non-invasive ventilation (NIV), terbutaline, inhaled helium and mechanical ventilation between cohorts of children admitted with status asthmaticus to the PICU treated with either IV dexamethasone (DM) or methylprednisolone (MP).
Eligibility Criteria
Inclusion Criteria
- Inclusion criteria are children 5 to 17 years of age with primary admission diagnoses of acute asthma exacerbation or status asthmaticus admitted to the PICU
Exclusion Criteria
- children with existing tracheostomy, cystic fibrosis, and pulmonary hypertension
Data sourced from ClinicalTrials.gov (NCT03900624). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.